New York State Approves Medicare Reimbursement of VidaMed's TUNA Procedure
TUNA Now Available to More Than 29 Million Men Age 50-Plus
FREMONT, Calif.--(BW HealthWire)--Feb. 7, 2000-- VidaMed, Inc. (NASDAQ: VIDA) today announced that the state of New York approved Medicare reimbursement of the Company's TUNA (Transurethral Needle Ablation) procedure for the treatment of benign prostatic hyperplasia (BPH) in hospitals, effective immediately.
New York, the 47th state to offer Medicare reimbursement of the TUNA procedure, has more than 2 million men over the age 50. With this addition, Medicare reimbursement of TUNA is now available to more than 29 million men over the age of 50 across the country.
"New York is the last of the top five Medicare populated states to approve reimbursement for the TUNA procedure, thereby affording more than 2 million potential patients and more than 900 urologists access to this safe, durable, and minimally invasive BPH treatment," commented Randy Lindholm, VidaMed's President and Chief Executive Officer. "We recently hired personnel in anticipation of this approval, and are ready to begin bringing the many advantages of TUNA to the men of New York. It is our belief that the more information known about BPH and treatment options, the more likely TUNA will be considered the treatment of choice after drug therapy has failed and before major surgery."
VidaMed designs, develops and markets technologically and clinically advanced cost-effective systems for the treatment of urological conditions. For investor information, please call (800) 363-2994 or visit the Company's Web site at www.vidamed.com.
Certain statements in this news release, contain forward-looking information. Actual results may vary significantly from those anticipated in such forward-looking statements due to risks and uncertainties, including the rate of adoption of the TUNA procedure by the medical community, the impact of competitive treatments, products and pricing, the development and effectiveness of the Company's sales organization and marketing efforts, continuing Medicare reimbursement and other risks, including those set forth in the Company's reports filed with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact:
VidaMed, Inc.
Randy Lindholm, President & CEO,
John Howe, Chief Financial Officer, 510/492-4900
www.vidamed.com
or
Lippert Heilshorn & Associates
Investor Contacts:
Bruce Voss (Bruce@lhai.com), 310/575-4848
Kim Sutton Golodetz (Kim@lhai.com), 212/838-3777
Media Contact:
Elissa Grabowski (Elissa@lhai.com), 212/838-3777
www.lhai.com
All Headlines
Additional Headlines
BW 02/07 03:59 New York State Approves Medicare Reimbursement of VidaMed's TUNA Procedure
BW 02/02 04:01 VidaMed Reports Record Fourth Quarter and Full Year Revenues
BW 02/01 04:01 Mitsubishi Corporation's Subsidiary to Distribute Vidamed TUNA System in Japan
BW 01/28 17:40 Datastream Systems, VidaMed, Zindart Limited OneSource Information Services and Tekelec Conference Calls to be Broadcast On Investor Broadcast Network Over the Internet
|
